#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Hugh Rienhoff Email
CEO . Imago BioSciences
South San Francisco, CA
LocationPrimary Email
How to contact Hugh Rienhoff
Join and see Hugh's contact info for free!Phone
Current Roles
Employees:
39Revenue:
$5.3MAbout
Our scientific efforts are aimed at developing drugs that improve the management of proliferative diseases of the bone marrow. Our clinical focus is on acute myeloid leukemia, myelodysplastic syndrome, polycythemia vera, myelofibrosis and essential thrombocythemia. These diseases share several features. They are diseases caused by acquired mutations in blood stem cells. To varying degrees, these mutations drive excessive growth of bone marrow cells, as well as alter their function. For example, myelofibrosis can be viewed as a chronic inflammatory disorder in which inflammatory cytokines and growth factors cause bone marrow cells to alter the architecture of and ultimately destroy the bone marrow. Imago BioSciences has developed inhibitors of the enzyme lysine-specific demethylase 1 (LSD1). This enzyme plays a critical role in regulating the growth and development of bone marrow cells. Our first clinical inhibitor of LSD1, bomedemstat (or IMG-7289) is being studied in patients with acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms including myelofibrosis. Future clinical studies are planned for other related diseases.Imago BioSciences Address
329 Oyster Point BlvdSouth San Francisco, CA
United States